The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement

@article{Cox2004TheRO,
  title={The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement},
  author={T. Cox and J. Aerts and G. Andria and M. Beck and N. Belmatoug and B. Bembi and R. Chertkoff and S. vom Dahl and D. Elstein and A. Erikson and M. Giralt and R. Heitner and C. Hollak and M. Hřeb{\'i}{\vc}ek and S. A. Lewis and A. Mehta and G. Pastores and A. Rolfs and M. S. S{\'a} Miranda and A. Zimran},
  journal={Journal of Inherited Metabolic Disease},
  year={2004},
  volume={26},
  pages={513-526}
}
  • T. Cox, J. Aerts, +17 authors A. Zimran
  • Published 2004
  • Medicine
  • Journal of Inherited Metabolic Disease
    • N-Butyldeoxynojirimycin (NB-DNJ, miglustat 'Zavesca') is an orallyactive iminosugar which inhibits the biosynthesis of macromolecular substrates that accumulate pathologically in glycosphingolipidoses. Clinical trials of NB-DNJ in patients with Gaucher's disease demonstrate the therapeutic potential of such substrate inhibitors in the glycolipid storage disorders. However, macrophage-targetted enzyme replacement using intravenous mannose-terminated human glucocerebrosidase (imiglucerase… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    222 Citations
    Highly Influential Citations
    6
    Background Citations
    60
    Methods Citations
    12
    Results Citations
    1
    222 Citations
    Citation Type

    Citation Type

    Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease
    • 33
    Imiglucerase and its use for the treatment of Gaucher's disease
    • 28
    Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
    • 7
    Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy
    • 39
    Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
    • 80
    • PDF
    An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
    • 27
    • PDF
    CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
    • 41
    Substrate reduction therapy of glycosphingolipid storage disorders
    • 140
    Review of miglustat for clinical management in Gaucher disease type 1
    • C. Ficicioglu
    • Medicine
    • Therapeutics and clinical risk management
    • 2008
    • 51
    • PDF
    N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice.
    • 8

    References

    SHOWING 1-10 OF 61 REFERENCES
    Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
    • 669
    Substrate reduction therapy of glycosphingolipid storage disorders
    • 140
    N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
    • 402
    • PDF
    Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources
    • 404
    Failure of Alglucerase Infused into Gaucher Disease Patients to Localize in Marrow Macrophages
    • 27
    The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases.
    • M. Tierney, J. Pottage, +7 authors J. Sherman
    • Biology, Medicine
    • Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
    • 1995
    • 43
    Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    • 1,083
    The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
    • 89
    Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
    • 88
    Replacement therapy with imiglucerase for type 1 Gaucher's disease
    • 101